Segment Information

9 Months Ended

Sep. 30, 2017

Segment Information

Segment Information

11.Segment Information

We currently operate as one operating segment with a focus on the development and commercialization of products to address the unmet needs of patients with chronic and life-threatening conditions. Our Chief Executive Officer, as our chief operating decision maker, manages and allocates resources to the operations of our company on a consolidated basis. This enables our Chief Executive Officer to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, and research and development projects that are in line with our long-term company-wide strategic goals.

Net product sales, cost of product sales and gross profit for each of our commercial products were as follows (in millions):

	Three Months Ended September 30,
2017	Remodulin		Tyvaso		Adcirca		Orenitram		Unituxin		Total
Net product sales	$	187.3	$	88.9	$	99.8	$	52.5	$	17.0	$	445.5
Cost of product sales	4.0		2.2		5.6		3.9		3.8		19.5
Gross profit	$	183.3	$	86.7	$	94.2	$	48.6	$	13.2	$	426.0
2016
Net product sales	$	152.4	$	101.8	$	96.0	$	40.7	$	17.3	$	408.2
Cost of product sales	3.7		5.8		5.5		5.2		3.4		23.6
Gross profit	$	148.7	$	96.0	$	90.5	$	35.5	$	13.9	$	384.6

	Nine Months Ended September 30,
2017	Remodulin		Tyvaso		Adcirca		Orenitram		Unituxin		Total
Net product sales	$	490.8	$	280.5	$	300.4	$	137.8	$	51.1	$	1,260.6
Cost of product sales	9.9		7.9		16.9		10.7		7.3		52.7
Gross profit	$	480.9	$	272.6	$	283.5	$	127.1	$	43.8	$	1,207.9
2016
Net product sales	$	451.1	$	311.0	$	259.5	$	118.9	$	49.3	$	1,189.8
Cost of product sales	4.3		12.9		15.0		7.9		4.2		44.3
Gross profit	$	446.8	$	298.1	$	244.5	$	111.0	$	45.1	$	1,145.5